ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 3, 2025 ...
ORIC Pharmaceuticals shares surge on potential data leak
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid ...
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website ...
Wedbush Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
Wedbush analyst David Nierengarten maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report) today and set a price target of ...
Morningstar3d
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that ...
Jones Trading maintains Buy on ORIC, $17 target on positive data
Jones Trading reiterated a Buy rating on ORIC Pharmaceuticals stock with a price target of $17.00, as shares traded at $11.23. The stock has shown remarkable momentum, gaining over 20% in the past ...
Seeking Alpha8d
ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data
ORIC Pharmaceuticals' ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. ORIC-114 shows strong CNS penetration and promising results in brain ...